{"product_id":"lucivande-vandetanib","title":"LuciVande 100 (Vandetanib)","description":"\u003cp\u003e\u003cstrong\u003eAbout Vandetanib \u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eVandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.\u003c\/p\u003e\u003ch3\u003eMedullary Thyroid Cancer\u003c\/h3\u003e\u003cp\u003eIndicated for treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease\u003c\/p\u003e\u003cp\u003e300 mg PO qDay with or without food\u003c\/p\u003e\u003cp\u003eContinued until disease progression or unacceptable toxicity occurs\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eDose Reduction\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade ≥3 toxicities: Reduce to 200 mg qDay; then further reduce to 100 mg qDay if necessary\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eInterrupt therapy\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eCorrected QT interval, Fridericia (QTcB) interval \u0026gt;500 msec: Resume at reduce dose once QTcF ≤450 msec\u003c\/li\u003e\n\u003cli\u003eGrade ≥3 toxicity: Resume at reduced dose once toxicity resolves to Grade \u0026lt;1\u003c\/li\u003e\n\u003cli\u003eRecurrent toxicities: Reduce dose to 100 mg once toxicity resolves to Grade \u0026lt;1, if continued treatment is warranted\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eCrCl ≥50 mL\/min: No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate (CrCl 30 to \u0026lt;50 mL\/min): Reduce starting dose to 200 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl \u0026lt;30 mL\/min): Not recommended\u003c\/li\u003e\n\u003cli\u003eEnd-stage renal disease requiring dialysis: Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (Child Pugh A): Dose adjustment not described in manufacturer's label\u003c\/li\u003e\n\u003cli\u003eModerate-to-severe (Child-Pugh B or C): Not recommended\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797957996587,"sku":"RL362025060601","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-06-0674.jpg?v=1787022294","url":"https:\/\/xomeds.com\/products\/lucivande-vandetanib","provider":"XOMEDS","version":"1.0","type":"link"}